Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC
Bullboard Posts
User Avatar Image
(0)
•••
Post by rgonlyfactsplson Oct 07, 2010 11:34am
507 Views
Post# 17540403

"too smart by a half"...

"too smart by a half"...

...sharing a dated but fav article based on a few of this morning's posts. Below is an excerpt from the article so can quickly decide if you want to read or not. And, nothing is time sensitive here (insight from the past) so suggest you read only when you have some spare time.

Note: Subject title of this post is reflective of the seven analysts in article below. NOT BNC posters.

* Not one of seven analysts who published a rating on Dendreon's stock recommended buying it ahead of the release of positive results on the prostate cancer vaccine Provenge that more than doubled the share price on Tuesday. For a time the price more than tripled.

Enjoy the read!

rg (long & deep on BNC)

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities